Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H ( (HK:6821) ) has issued an update.
Asymchem Laboratories (Tianjin) Co., Ltd. announced the election of a new board session as the term of the fourth session concludes. The fifth session will include nine directors, with a mix of executive, non-executive, and independent non-executive directors. The board also proposed the appointment of Mr. Xie Weikai as an independent non-executive director, bringing extensive experience in equity financing and corporate governance to the company. This restructuring aims to strengthen the company’s governance and strategic direction, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (HK:6821) stock is a Hold with a HK$45.50 price target. To see the full list of analyst forecasts on Asymchem Laboratories (Tianjin) Co., Ltd. Class H stock, see the HK:6821 Stock Forecast page.
More about Asymchem Laboratories (Tianjin) Co., Ltd. Class H
Asymchem Laboratories (Tianjin) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, primarily engaged in the pharmaceutical industry. The company focuses on providing comprehensive services in drug development and manufacturing, catering to the needs of the global pharmaceutical market.
Average Trading Volume: 897,871
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.12B
For detailed information about 6821 stock, go to TipRanks’ Stock Analysis page.